This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Edwards Lifesciences granted injunction against Meril; UPC confirms jurisdiction

By Inbar Preiss ( April 4, 2025, 15:18 GMT | Insight) -- The Unified Patent Court has granted Edwards Lifesciences an injunction against Meril Life Sciences, finding that Meril’s heart valve products infringe Edwards’ European patent. The court confirmed it had jurisdiction over Meril’s Indian parent company and its European subsidiaries, citing a commercial link and the same alleged infringement across national designations. On top of injunctive relief, Edwards won orders for product recall, destruction, and provisional damages, while Meril’s arguments on jurisdiction, invalidity and public interest were rejected.Edwards Lifesciences Corporation has secured an injunction against Meril Life Sciences from the Unified Patent Court. The Local Division Munich decision published today upheld Edwards’ patent and found it novel over prior art....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections